Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

69.31
-3.1400-4.33%
Pre-market: 69.750.4400+0.63%06:19 EDT
Volume:2.58M
Turnover:178.90M
Market Cap:9.64B
PE:-9.65
High:72.19
Open:72.13
Low:68.55
Close:72.45
52wk High:88.31
52wk Low:47.22
Shares:139.02M
Float Shares:138.02M
Volume Ratio:1.60
T/O Rate:1.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-55.54
PE(LYR):-10.60

Loading ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 14

Cytokinetics is Maintained at Overweight by JP Morgan

Dow Jones
·
Aug 13

Cytokinetics Files Patent Suit to Protect MYQORZO Franchise

TIPRANKS
·
Aug 13

Cytokinetics - Files Complaint Against Bristol-Myers Squibb and Myokardia - SEC Filing

THOMSON REUTERS
·
Aug 13

Cytokinetics - Demands Trial by Jury on All Triable Issues - SEC Filing

THOMSON REUTERS
·
Aug 13

Cytokinetics - Seeks Injunction Against Litigation or Infringement Claims on Myqorzo(Aficamten) - SEC Filing

THOMSON REUTERS
·
Aug 13

Cytokinetics Sues Bristol Myers, MyoKardia Seeking Ruling on Myqorzo Patent Dispute

Reuters
·
Aug 13

U.S. Research Roundup-Airbnb, Five Below, Silgan Holdings

Reuters
·
Aug 13

Cytokinetics, Incorporated : JP Morgan Raises Target Price to $103 from $97

THOMSON REUTERS
·
Aug 13

Truist Financial Keeps Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
Aug 13

Cytokinetics CEO Robert I. Blum Sells 7,500 Common Shares for $575,700

Reuters
·
Aug 11

Cytokinetics is Maintained at Buy by Truist Securities

Dow Jones
·
Aug 11

Cytokinetics price target raised to $112 from $106 at Truist

TIPRANKS
·
Aug 10

Cytokinetics, Incorporated : Leerink Partners Raises Target Price to $103 from $100

THOMSON REUTERS
·
Aug 10

Truist Adjusts Price Target on Cytokinetics to $112 From $106, Maintains Buy Rating

MT Newswires Live
·
Aug 10

Cytokinetics' Q2 Beat Highlights Myqorzo Launch Strength, RBC Says

MT Newswires Live
·
Aug 08

Cytokinetics price target raised to $85 from $83 at BofA

TIPRANKS
·
Aug 07

Cytokinetics Price Target Raised to $112.00/Share from $102.00 by Needham

Dow Jones
·
Aug 07

RBC Capital Adjusts PT on Cytokinetics to $112 From $117, Maintains Outperform Rating

MT Newswires Live
·
Aug 07

Cytokinetics price target raised to $110 from $105 at Citizens

TIPRANKS
·
Aug 07